Healthcare InvestmentADARx Pharmaceuticals is seeking fresh public-market capital despite entering 2026 with $427.3 million in cash, using the offering to support a wide clinical agenda across complement, hereditary angioedema and thrombosis-related programs. The move adds to this year's biotech IPO wave while showing that investors are again being asked to fund platform breadth, not just a single lead asset.
Michael Torres·Sep 7, 2026
Biotech InnovationPelacarsen was being watched as the first phase 3 attempt to prove that lowering lipoprotein(a) changes cardiovascular outcomes, not just a biomarker. Novartis now says that link was not shown in the overall study population, shifting attention to whether deeper suppression or different trial designs from Amgen and Eli Lilly can produce a different result.
Michael Torres·Sep 5, 2026 
Biopharmaceutical IndustryThe Menarini Group has agreed to collaborate with Gan & Lee Pharmaceuticals on bofanglutide, a once-every-two-weeks GLP-1 candidate. Beyond the €62 million upfront payment, Gan & Lee could receive up to €664 million in milestones plus double-digit royalties on sales.
Michael Torres·Sep 4, 2026 
Regulatory & PolicyThe program is aimed at replacing a centralized manufacturing model with faster, more accessible production for personalized RNA therapies. Early work will focus on cancer, rare genetic conditions and chronic diseases, with several biotech and academic teams assigned distinct manufacturing and quality-control roles.
Michael Torres·Sep 3, 2026 
Regulatory & PolicyThe Medicines and Healthcare products Regulatory Agency said its move followed a review of all available evidence and concerns about the integrity and reliability of data from the study supporting the medicine’s authorization. Amgen said it disagrees with the U.K. decision and is building its defense of Tavneos with an independent analysis and patient testimonials.
Michael Torres·Sep 2, 2026 
Biopharmaceutical IndustryAlteogen said Novartis will hold multiple options to secure exclusive rights to develop drugs using ALT-B4, though the release did not disclose an upfront fee. The agreement extends a run of partnerings that has turned the Korean company into one of the main challengers to Halozyme Therapeutics in subcutaneous drug delivery.
Michael Torres·Sep 2, 2026 
Biotech InnovationOne paper reports prime assembly, a method that uses prime editors to generate matching 3′-flaps on genomic DNA and donor DNA for precise replacement or insertion. A second paper describes donor-complementary prime editing, or DoPE, which pairs overhang double-stranded DNA donors with engineered guide RNAs to support one-step insertions up to 12.5 kilobases.
Michael Torres·Aug 29, 2026 
Biopharmaceutical IndustryAstraZeneca and Amgen reported that Tezspire significantly improved histologic remission and dysphagia symptoms at 24 weeks in the Phase 3 CROSSING study, with effects sustained through 52 weeks. The announcement matters because Dupixent currently owns the biologic category in eosinophilic esophagitis, yet Tezspire may have a practical differentiator in dosing frequency if the full efficacy data are competitive.
Michael Torres·Aug 28, 2026 
Biopharmaceutical IndustryThe drug will be sold as Lisraya and taken once daily. For Roivant, the approval turns a rare-disease immunology program into a commercial product in a U.S. market the company says includes between 40,000 and 70,000 people.
Michael Torres·Aug 28, 2026 
Regulatory & PolicyThe article spans several companies, but the common thread is policy and review risk shaping biotech valuations and strategy. Capricor’s extension, Moderna’s stock move after cancer vaccine data, and the naming of a commissioner nominee each show how quickly sentiment can shift when the FDA timetable or leadership picture changes.
Michael Torres·Aug 27, 2026 
Medical TechnologyRefluxStop is designed to reduce or stop acid from entering the oesophagus through an implant placed on the upper part of the stomach via keyhole surgery. The approval brings the device into the U.S. after years on the European market, but Implantica is signaling a gradual commercial rollout centered on selected centers and physician training.
Michael Torres·Aug 25, 2026 
Regulatory & PolicyCapricor’s original Aug. 22 action date passed without a decision, and the company now says the FDA classified its latest submission as a major amendment. Strategically, the amendment shifts the center of gravity back to the trial’s primary endpoint after a contentious review process that spent substantial time on a cardiac-related secondary endpoint.
Michael Torres·Aug 25, 2026 